Viewing Study NCT00743795

Home Icon Home Search Icon Search Certify Doc Icon Certify Doc Certify Doc Icon Genes Certify Doc Icon Clinical Trials Certify Doc Icon CompTox Processes Icon DrugMatrix Open Targets Icon Open Targets Processes Icon Products Support Icon Support Bugs Icon Bugs
Main Search Make This Study a Gene Therapy Make This Study a Not Gene Therapy Report Bug
Ignite Creation Date: 2025-12-24 @ 1:20 PM
Ignite Modification Date: 2026-02-02 @ 5:36 PM
Study NCT ID: NCT00743795
Status: COMPLETED
Last Update Posted: 2013-11-05
First Post: 2008-08-27
Is Gene Therapy: True
Has Adverse Events: False
Brief Title: Safety, Tolerability, and Antiviral Activity of 24 or 48 Weeks of GS-9190 in Combination With Peginterferon Alfa 2a and Ribavirin for the Treatment of Genotype-1 Chronic HCV Infection
Sponsor: Gilead Sciences
Organization:
Overview Dates Organization Conditions Design Enrollment Locations Outcomes Modules Raw JSON

Conditions & Keywords Data

Conditions:

Conditions

Condition Brief Condition Text View
None HCV Infection View
Keywords:

Keywords

Keyword Brief Keyword Text View
None Hepatitis C View
None HCV View
None Rapid Virologic Response View
None Sustained Virologic Response View
None HCV RNA View
None Polymerase inhibitor View
None GS-9190 View